A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology.

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

In a small percentage of patients, T-cell accumulation is so extensive that disfiguring nodules and tumors develop (see Figure 4). As the tumors grow they may ulcerate and lead to considerable ...

T-cell skin lymphomas are more common than B-cell skin lymphomas. Cutaneous T-cell lymphoma (CTCL) occurs when a mutation causes the cell to divide too quickly and stay alive too long. The ...

Investigators found that denileukin diftitox, which targets the interleukin-2 receptor, achieves objective response rates in 44% of patients with cutaneous T-cell lymphoma, with a median duration ...

Cutaneous T-cell lymphoma is a group of rare blood cancers that affects the skin. Nine patients have been enrolled and treated with HyBryte over up to 54 weeks. Also Read: Soligenix Kickstarts ...

Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that the ...

My research is aimed at developing an improved understanding of new therapies for patients with several less-common types of lymphoma, including T cell lymphomas, cutaneous (skin) lymphomas, Hodgkin ...

utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active ...

Phototherapy involves the use of ultraviolet light for the treatment of skin disease and many dermatologists have phototherapy units in their offices. With these units, ultraviolet light of ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology. Cutaneous T ...

"The complete response rate, consistent treatment response and safety profile across multiple clinical studies to date with HyBryte™ has been exciting to see," noted Dr. Kim, Principal ...